U.S. Markets closed

Mustang Bio to Present at the Cell & Gene Therapy USA Congress 2019

NEW YORK, May 13, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced two presentations at the Cell & Gene Therapy USA Congress 2019, to be held May 14-15, 2019, at the John B. Hynes Veterans Memorial Convention Center in Boston, MA. 

Details on the presentations are as follows:

Title: From Academia to Industry: Lessons Learned in the Development of CAR-T Therapies
Presenter: Knut Niss, Ph.D., Chief Technology Officer, Mustang Bio
Session: Bringing Pre-clinical Cellular & Gene Therapies to Patients: Development, Commercialization, Market Access, Future Outlook
Date and Time: Tuesday, May 14, 2019, 1:50 p.m. EDT

Title: CMC Analytics Challenges for CAR-T & TCR T Cell-Based Therapies
Presenter: Junxia Wang, M.D., Ph.D., Director of Analytical Development, Mustang Bio
Session: Cell & Gene Therapy Development and Clinical Trials
Date and Time: Wednesday, May 15, 2019, 10 a.m. EDT

For additional information, please visit: https://www.oxfordglobal.co.uk/celltherapyusa-congress/.

About Mustang Bio
Mustang Bio, Inc. (“Mustang”) is a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for X­SCID. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U.S. Securities and Exchange Commission. Mustang was founded by Fortress Biotech, Inc. (FBIO). For more information, visit www.mustangbio.com.

Forward‐Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Company Contacts:
Jaclyn Jaffe and William Begien
Mustang Bio, Inc.
(781) 652-4500

Investor Relations Contact:
Daniel Ferry
LifeSci Advisors, LLC
(617) 535-7746

Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 940-0135